35. EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) IN THE MANAGEMENT OF PEDIATRIC PATIENTS WITH GRADE IV HAND, FOOT AND MOUTH DISEASE: A REPORT OF THREE CASES
Main Article Content
Abstract
Background: Severe hand, foot and mouth disease (HFMD) caused by Enterovirus A71 (EV-A71) may lead to acute pulmonary edema, central nervous system involvement, and cardiopulmonary failure, potentially resulting in death without timely intensive care. Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has emerged as a salvage therapy in cases unresponsive to conventional treatment. However, clinical data regarding ECMO in pediatric EV-A71-associated HFMD grade IV remain limited in Vietnam.
Objectives and methods:We report the first three pediatric cases in Vietnam with EV-A71-associated HFMD grade IV treated with combined VA-ECMO and continuous renal replacement therapy (CRRT) at Children's Hospital 2 in 2023.
Results: All three patients experienced clinical deterioration on illness day 3, presenting with pulmonary edema, autonomic nervous system dysregulation, and acute heart failure. Despite early initiation of CRRT (within 2–2,5 hours of hospital admission), all developed cardiogenic shock with a reduced ejection fraction (EF ~30%) and refractory ventricular arrhythmias, necessitating ECMO support. Hemodynamic and metabolic parameters significantly improved within 8–24 hours of ECMO initiation. Cardiac function nearly normalized between 36–144 hours. Brain MRI in all cases revealed brainstem involvement. All patients recovered consciousness and were discharged in good condition.
Conclusion: VA-ECMO combined with CRRT may be a life-saving intervention for children with EV-A71-associated HFMD grade IV complicated by cardiopulmonary failure and refractory arrhythmias. Early initiation is key to improving outcomes and minimizing neurological sequelae.
Article Details
Keywords
Hand, foot and mouth disease grade IV; ventricular arrhythmia; ECMO; CRRT.
References
[2] World Health Organization (2011). A guide to clinical management and public health response for hand, foot and mouth (HFMD). Available from: https://apps.who.int/iris/handle/10665/204730.
[3] Jan SL, Lin SJ, Fu YC, Chi CS, Wang CC, Wei HJ, et al.(2010). Extracorporeal life support for treatment of children with enterovirus 71 infection-related cardiopulmonary failure. Intensive Care Med. 36:520-7.
[4] Jan SL, F.Y., Chi CS, Lee HF, Huang FL, Wang CC, et al (2021). Catecholamine-Induced Secondary Takotsubo Syndrome in Children with Severe Enterovirus 71 Infection and Acute Heart Failure: A 20-year Experience of a Single Institute. Front Cardiovasc Med. 8:752232.
[5] Wang C, Cui Y, Zhu Y, Wang F, Rong Q, Zhang Y (2019). Continuous hemodiafiltration as a rescue therapy for patients with cardiopulmonary failure caused by enterovirus-71: a retrospective observational study in a PICU. BMC Infect Dis. 19:866.
[6] Jones E, Pillay TD, Liu F, Luo L, Bazo-Alvarez JC, Yuan C, et al (2018). Outcomes following severe hand foot and mouth disease: A systematic review and meta-analysis. Eur J Paediatr Neurol. 22:763-773.
[7] Cai K, Wang Y, Guo Z, Yu H, Li H, Zhang L, et al (2019). Clinical characteristics and managements of severe hand, foot and mouth disease caused by enterovirus A71 and coxsackievirus A16 in Shanghai, China. BMC Infect Dis. 19:285.
[8] Wang SM, Lei HY, Huang KJ, Wu JM, Wang JR, Yu CK, et al (2003). Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema. J Infect Dis.188:564–570.